BusinessMVP

INDIANAPOLIS, April 4, 2017 /PRNewswire/ — Students from Ohio University’s Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company’s (NYSE: LLY) innovative rotation program for aspiring physicians. Launched in early 2014, the program provides students with hands-on experience in a range of pharmaceutical business activities, from drug discovery and development to bioethics and […]

Significant investment in manufacturing diabetes medicines continues with new $85 million commitment in Indianapolis $5 billion invested in its U.S. operations over the last decade; more favorable tax climate could lead to additional U.S. investments INDIANAPOLIS, March 24, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced plans to invest $850 million in its […]

Jointly developed research projects will study diabetes healthcare outcomes for the Latino population SANTA BARBARA, Calif. and INDIANAPOLIS, March 23, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino people affected by diabetes through enhanced research, education and care. […]

Abemaciclib, in combination with fulvestrant, was superior to fulvestrant plus placebo in patients with HR+, HER2- advanced breast cancer INDIANAPOLIS, March 20, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent […]

EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes Heart failure affects 26 million people worldwide, and 5.7 million people in the U.S., and is associated with high morbidity and mortality EMPEROR HF will include approximately 7,000 […]

Lilly to present head-to-head 24-week data comparing the efficacy and safety of Taltz and Stelara for the treatment of moderate-to-severe plaque psoriasis INDIANAPOLIS, March 4, 2017 /CNW/ — Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated superior efficacy at 24 weeks compared to patients […]

New Relationship Builds on Partnership with Roush Fenway Racing™ DAYTONA BEACH, Fla., March 3, 2017 /PRNewswire/ — NASCAR® and Lilly Diabetes announced today that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the sanctioning body. The new collaboration designates Lilly Diabetes as the “Official Diabetes Health Partner of NASCAR.” The […]

Fionnuala Walsh retiring, Johna Norton promoted; Bart Peterson leaving to pursue external interests INDIANAPOLIS, March 2, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced changes in its executive committee. Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after […]

INDIANAPOLIS, March 1, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017. As of the expiration […]

INDIANAPOLIS, Feb. 28, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the American Academy of Dermatology (AAD), which will take place March 3-7, 2017, in Orlando, Fla. Lilly will […]